Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Aims for 1 Trillion Yen Sales in Emerging Markets by FY2030
March 15, 2021
- Actemra-Remdesivir COVID-19 Combo Trial Fails, Chugai to Gauge Overall Data for Submission
March 12, 2021
- Sosei to Get US$2.5 Million Milestone Payment from Formosa
March 12, 2021
- Me Pharma Eyes Production of 1 Billion Tablets in FY2021, Sales Buoyed by Low Prices
March 12, 2021
- 5 Lysosomal Disease Drugs Now Available for Home Care: Sanofi
March 12, 2021
- Astellas Seeks Japan Nod for Padcev
March 12, 2021
- Keytruda Filed for TMB-H Solid Tumors in Japan: MSD
March 12, 2021
- Takeda, ANA to Test Drone Drug Delivery to Remote Islands in Nagasaki
March 12, 2021
- Kobayashi Kako to Invite Outsider to Take Over Top Post: Biz Improvement Plan
March 11, 2021
- Nichi-Iko to Stop Supply of 4 APIs/8 Products as Stocks Run Out
March 11, 2021
- JMA Affiliate Data Operator Poised to Provide RWD from NHO Hospitals to Drug Makers
March 11, 2021
- Takeda to Buy Out T-Cell Engager Specialist Maverick for US$525 Million
March 11, 2021
- Nichi-Iko Drug Supply Delayed as Customers Flock to Place Orders
March 10, 2021
- 70% of Major Products Fall Victim to Off-Year Drug Re-Pricing: Jiho Tally
March 10, 2021
- JCR Terminates Temcell Development for Epidermolysis Bullosa
March 10, 2021
- Top-Tier Drug Makers Face 2-4% Cuts, Mid-Sized Firms 6-8% in Japan’s First Off-Year Re-Pricing: Tally
March 9, 2021
- Top-3 Generic Makers Hit with Average 9.8% Price Cut in Off-Year Revision: Jiho Tally
March 9, 2021
- Rohto Kicks Off Japan PIIa of JAK Inhibitor Delgocitinib for Dry Eye Symptoms
March 9, 2021
- Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
- Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…